In immediate danger? Call 911.In the United States, call or text 988 for 24/7 crisis support.
Submit a practice
Menu

Understand the evidence and the distinction

Ketamine and Depression

Ketamine has approved anesthetic uses, while ketamine products are not FDA-approved for psychiatric disorders. Some clinicians use ketamine off label for depression, which makes formulation, oversight, evidence, and monitoring especially important to understand.

Find appropriate carePrepare your questions

What to know first

  • Ketamine and esketamine are related, but they are not interchangeable products or regulatory pathways.
  • Compounded ketamine products are not FDA-approved for psychiatric disorders.
  • Route, dose, setting, monitoring, prescriber qualifications, and follow-up all matter.
  • Marketing claims should never replace a psychiatric evaluation or a clear emergency plan.

Why the terminology gets confusing

Patients often see ketamine, IV ketamine, compounded nasal ketamine, oral ketamine, and SPRAVATO discussed as if they are one treatment. They are not.

SPRAVATO is an FDA-approved esketamine product with a defined label and REMS. Ketamine has FDA-approved anesthetic uses, while psychiatric use is off label. Compounded forms have additional quality, dosing, and supervision questions that should be discussed directly with a qualified clinician.

Questions that matter more than a headline

Ask exactly what product is being offered, whether the use is FDA-approved or off label, who prescribes it, how you are monitored, and what follow-up is built into care.

  • What formulation and route are being used?
  • Is this an FDA-approved use, an off-label use, or a compounded product?
  • Who evaluates diagnosis, bipolar symptoms, substance-use risk, blood pressure, medications, and safety?
  • What monitoring happens during and after treatment?
  • How will benefit, adverse effects, ongoing need, and stopping decisions be assessed?

Why at-home claims deserve caution

FDA has warned about risks associated with compounded ketamine products used for psychiatric disorders, including use without onsite healthcare monitoring.

A convenient delivery model does not remove the need for diagnostic review, safe prescribing, monitoring, and a plan for adverse effects or worsening symptoms. Patients should understand who is responsible at every step.

Keep the decision inside a complete care plan

Ketamine should not be framed as a stand-alone cure or a replacement for thoughtful psychiatric care.

A responsible plan may include medication review, psychotherapy, sleep and substance-use assessment, treatment measurement, family or caregiver support when appropriate, and a clear escalation pathway for urgent safety concerns.

Common questions

Questions patients and families ask

Is ketamine FDA-approved for depression?

Ketamine products are not FDA-approved for psychiatric disorders. SPRAVATO, which contains esketamine, has specific FDA-approved depression indications and a REMS-controlled treatment pathway.

Does off-label mean illegal or automatically unsafe?

No. Clinicians may prescribe approved drugs off label, but patients should understand the evidence, product, route, monitoring, alternatives, and why the clinician believes it fits their situation.

Should I buy compounded ketamine online?

Do not make that decision from marketing alone. FDA has identified safety concerns with compounded ketamine used for psychiatric disorders, particularly when care lacks onsite monitoring. Discuss the exact product and care model with a qualified clinician.

Primary sources

Review the evidence directly

Source links support education, not a personal treatment recommendation. Exact candidacy and risk must be assessed by a qualified clinician.

Continue learning

Understand SPRAVATO / esketamineCompare advanced treatment pathsUnderstand treatment-resistant depression